The use of immunotherapy for the treatment of tuberculosis
- 14 March 2018
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 12 (5) , 427-440
Abstract
Introduction: Tuberculosis (TB) is the first cause of mortality by a single infectious agent in the world, causing more than one million deaths worldwide as reported by the World Health Organization (WHO). For the optimal control of TB infection, a protective immune response that limits bacterial spread without causing damage to the host is essential. Although most healthy individuals are capable of generating protective responses, patients who suffer pulmonary TB commonly present a defective immune function. Areas covered: We intend to highlight the potential of novel immunotherapeutic strategies that enhance and promote effective immune responses. The following methodology was undertaken for establishing a literature search: the authors used PubMed to search for ‘Pulmonary Tuberculosis’ and keywords that denoted the novel immunotherapeutic strategies discussed in length in the text including antibodies, antimicrobial peptides, cell therapy, cytokines and gene therapy. Expert commentary: The current therapeutic regimens for this disease are complex and involve the prolonged use of multiple antibiotics with diverse side effects that lead to therapeutic failure and bacterial resistance. The standard appliance of immunotherapy and its deployment to vulnerable populations will require coordinated work and may serve as a powerful tool to combat the ensuing threat of TB.Keywords
Funding Information
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (2015-1/115)
This publication has 125 references indexed in Scilit:
- Prominent role for T cell-derived Tumour Necrosis Factor for sustained control of Mycobacterium tuberculosis infectionScientific Reports, 2013
- Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammationProceedings of the National Academy of Sciences, 2012
- Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucoseProceedings of the National Academy of Sciences, 2011
- Mycobacterium tuberculosisevades host immunity by recruiting mesenchymal stem cellsProceedings of the National Academy of Sciences, 2010
- IL-17 and Th17 cells in tuberculosisCytokine & Growth Factor Reviews, 2010
- Kinetics and cellular sources of cathelicidin during the course of experimental latent tuberculous infection and progressive pulmonary tuberculosisClinical and Experimental Immunology, 2010
- Analytical and Functional Aspects of Antibody SialylationJournal of Clinical Immunology, 2010
- Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16kDa protein in a model of progressive pulmonary infectionInternational Journal of Medical Microbiology, 2009
- AMPed up immunity: how antimicrobial peptides have multiple roles in immune defenseTrends in Immunology, 2009
- A combination of a transforming growth factor-β antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosisClinical and Experimental Immunology, 2006